In vitro activity of daptomycin against methicillin-resistant Staphylococcus aureus, including heterogeneously glycopeptide-resistant strains

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 9, 2006, Pages 3189-3191

  Diederen, Bram M W ^b   Van Duijn, Inge ^a   Willemse, Piet ^a   Kluytmans, Jan A J W ^a  

^a AMPHIA HOSPITAL   (Netherlands)

^b CPRLab   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; CLINDAMYCIN; COAGULASE; COTRIMOXAZOLE; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; OXACILLIN; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL INFECTION; BACTERIUM ISOLATE; GRAM POSITIVE BACTERIUM; HETEROGENEOUSLY GLYCOPEPTIDE RESISTANT METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MECA GENE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NETHERLANDS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STRAIN IDENTIFICATION;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; GLYCOPEPTIDES; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS;

EID: 33748712885     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00526-06     Document Type: Article

References (21)

1. Archer, G. L. 1998. Staphylococcus aureus: a well-armed pathogen. Clin. Infect. Dis. 26:1179-1181.
2. Barry, A. L., P. C. Fuchs, and S. D. Brown. 2001. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob. Agents Chemother. 45:1919-1922.
3. Carpenter, C. F., and H. F. Chambers. 2004. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin. Infect. Dis. 38:994-1000.
4. Chang, S., D. M. Sievert, J. C. Hageman, M. L. Boulton, F. C. Tenover, F. P. Downes, S. Shah, J. T. Rudrik, G. R. Pupp, W. J. Brown, D. Cardo, S. K. Fridkin, et al. 2003. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 348:1342-1347.
5. Cosgrove, S. E., Y. Qi, K. S. Kaye, S. Harbath, A. W. Karchmer, and Y. Carmeli. 2005. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect. Control Hosp. Epidemiol. 26:166-174.
6. Cui, L., E. Tominaga, H. Neoh, and K. Hiramatsu. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:1079-1082.
7. Fluit, A. C., F. J. Schmitz, J. Verhoef, and D. Milatovic. 2004. In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants. Antimicrob. Agents Chemother. 48:1007-1011.
8. Fuchs, P. C., A. L. Barry, and S. D. Brown. 2002. In vitro bactericidal activity of daptomycin against staphylococci. J. Antimicrob. Chemother. 49:467-470.
9. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136.
10. Kluytmans, J., A. Van Griethuysen, P. Willemse, and P. Van Keulen. 2002. Performance of CHROMagar selective medium and oxacillin resistance screening agar base for identifying Staphylococcus aureus and detecting methicillin resistance. J. Clin. Microbiol. 40:2480-2482.
11. National Committee for Clinical Laboratory Standards. 2006. Performance standards for antimicrobial susceptibility testing. Approved standard M100-S16. National Committee for Clinical Laboratory Standards, Wayne, Pa.
12. National Nosocomial Infections Surveillance System. 2004. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control 32:470-485.
13. Patel, J. B., L. A. Jevitt, J. Hageman, L. C. McDonald, and F. C. Tenover. 2006. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin. Infect. Dis. 42:1652-1653.
14. Ryhak, M. J., E. Hershberger, T. Moldovan, and R. G. Grucz. 2000. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin- dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob. Agents Chemother. 44:1062-1066.
15. Sader, H. S., P. R. Rhomberg, and R. N. Jones. 2005. Bactericidal activity of vancomycin and daptomycin tested against heterogeneous and homogeneous vancomycin-intermediate Staphylococcus aureus (hVISA and VISA) strains, p. 978. In Program and abstracts book, 15th European Congress of Clinical Microbiology and Infectious Diseases. European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark.
16. Sakoulas, G., J. Alder, G. M. Eliopoulos, R. C. Moellering, C. Thauvin-Eliopoulos, and G. M. Eliopoulos. 2005. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob. Agents Chemother. 50:1581-1585.
17. Schriever, C., C. Fernandez, K. Rodvold, and L. Danziger. 2005. Daptomycin: a novel cyclic lipopeptide antimicrobial. Am. J. Health Syst. Pharm. 62:1145-1158.
18. Silverman, J. A., N. Oliver, O. Andrew, and T. Li. 2001. Resistance studies with daptomycin. Antimicrob. Agents Chemother. 45:1799-1802.
19. van Griethuysen, A. J., M. Pouw, N. van Leeuwen, M. Heck, P. Willemse, A. Buiting, and J. Kluytmans. 1999. Rapid slide latex agglutination test for detection of methicillin resistance in Staphylococcus aureus. J. Clin. Microbiol. 37:2789-2792.
20. van Griethuysen, A. J., A. van't Veen, A. Buiting, T. Walsh, and J. Kluytmans. 2003. High percentage of methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to glycopeptides in The Netherlands. J. Clin. Microbiol. 41:2487-2491.
21. Walsh, T. R., A. Bolmström, A. Qwärnström, P. Ho, M. Wootton, R. A. Howe, A. P. MacGowan, and D. Diekema. 2001. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J. Clin. Microbiol. 39:2439-2444.